Soligenix, Inc.
SNGXSoligenix, Inc. in brief
Soligenix, Inc. is a listed company in the Biotechnology industry, based in Princeton, New Jersey, USA. Its market value was $9 M on 30 October 2026, which makes it the 26,155th largest listed company in the world and the 4,331st largest in the USA on this site. It employs about 14 people and Christopher J. Schaber is its chief executive. Its largest product and service lines by sales in 2024 were Grant revenue (100%). Its shares trade under the symbol SNGX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Soligenix, Inc.
We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.
Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the first Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study and agreement from the European Medicines Agency on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, we began patient enrollment during December 2024 for the second Phase 3 study called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2). We anticipate top-line results in the second half of 2026. Upon successful completion of the Phase 3 FLASH2 study, regulatory approval will be sought to support potential commercialization worldwide.
From the company's annual report filed with the US SEC: read the report
Soligenix, Inc. timeline
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1996
- ✎Renamed Endorex CorpFormerly Immunotherapeutics Inc.
- 2001
- ✎Renamed Dor Biopharma IncFormerly Endorex Corp.
- 2009
- ✎Renamed Soligenix, Inc.Formerly Dor Biopharma Inc.
Events of Soligenix, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,355 (Jan 2020) · #4,183 (Jan 2021) · #5,180 (Jan 2022) · #5,112 (Dec 2022) · #5,619 (Jul 2023) · #4,534 (Jan 2024) · #2,360 (Mar 2026) · #4,064 (Aug 2026) · #4,293 (Oct 2026) · #4,334 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.6×
- Free cash flow yield
- -118.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -209.5%
- Liabilities / assets
- 42.6%
- Net debt
- $-8M
- Revenue growth
- -11.6%
- R&D / revenue
- 394.0%
- Profit per employee
- $-791 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-12M | $-11M | — |
| Dec 2024 | — | — | $-9M | $-8M | — |
| Dec 2023 | $1M | -11.6% | $-8M | $-6M | -731.0% |
| Dec 2022 | $1M | +15.9% | $-14M | $-14M | -1452.6% |
| Dec 2021 | $1M | -65.3% | $-13M | $-13M | -1530.5% |
| Dec 2020 | $2M | -49.0% | $-19M | $-18M | -749.6% |
| Dec 2019 | $5M | -11.6% | $-11M | $-9M | -202.2% |
| Dec 2018 | $5M | — | $-9M | $-9M | -169.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-10M | $0M | $-10M | $-2.14 | — |
| Dec 2024 | $-8M | — | — | $-4.98 | — |
| Dec 2023 | $-9M | — | — | $-12.66 | — |
| Dec 2022 | $-13M | — | — | $-4.81 | — |
| Dec 2021 | $-12M | — | — | $-4.69 | — |
| Dec 2020 | $-11M | — | — | $-0.64 | — |
| Dec 2019 | $-8M | — | — | $-0.48 | — |
| Dec 2018 | $-7M | — | — | $-0.68 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Sep 21, 20268-KCurrent reportBylaws amended · Shareholder vote · Other events
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 2026DEF 14AProxy statement
- Jun 26, 20268-KCurrent reportOther events
- Jun 12, 20268-KCurrent reportListing notice · Directors or officers changed · Other events
- May 28, 20268-KCurrent reportOther events
- May 8, 202610-QQuarterly report · period to Mar 2026
- Apr 28, 20268-KCurrent reportOther events
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Feb 12, 20268-KCurrent reportOther events
- Jan 23, 20268-KCurrent reportOther events
Official filings of Soligenix, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-12 M
- Net income
- $-11 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $9 M
- Total liabilities
- $4 M
- Total equity
- $5 M
As of December-2025
Top 23 institutional investors in Soligenix, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Citadel Advisors LLC | 628,136 | +418,629 (+199.82%) | 2.69% | $0 M | Nov 16, 2026 |
| 2 | XTX Topco Ltd | 146,074 | -11,045 (-7.03%) | 0.63% | $0 M | Nov 16, 2026 |
| 3 | Geode Capital Management, LLC | 105,616 | -14,651 (-12.18%) | 0.45% | $0 M | Nov 6, 2026 |
| 4 | Vanguard Capital Management LLC | 81,005 | 0 (0.00%) | 0.35% | $0 M | Nov 13, 2026 |
| 5 | Jane Street Group, LLC | 62,709 | -144,783 (-69.78%) | 0.27% | $0 M | Nov 12, 2026 |
| 6 | StoneX Group Inc. | 56,709 | New | 0.24% | $0 M | Nov 3, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 53,914 | 0 (0.00%) | 0.23% | $0 M | Nov 13, 2026 |
| 8 | Renaissance Technologies LLC | 44,900 | New | 0.19% | $0 M | Nov 12, 2026 |
| 9 | Northern Trust Corp | 38,046 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 10 | Virtu Financial LLC | 19,596 | -41,307 (-67.82%) | 0.08% | $0 M | Nov 17, 2026 |
| 11 | Two Sigma Securities, LLC | 13,066 | New | 0.06% | $0 M | Nov 16, 2026 |
| 12 | Citigroup Inc | 9,961 | New | 0.04% | $0 M | Nov 4, 2026 |
| 13 | Morgan Stanley | 3,592 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 14 | UBS Group AG | 3,355 | New | 0.01% | $0 M | Nov 10, 2026 |
| 15 | Wells Fargo & Company/mn | 1,550 | New | 0.01% | $0 M | Nov 16, 2026 |
| 16 | Jones Financial Companies Lllp | 1,236 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 17 | Plante Moran Financial Advisors, LLC | 209 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 18 | Royal Bank Of Canada | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 19 | SBI Securities Co., Ltd. | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 20 | Jpmorgan Chase & Co | 1 | -244 (-99.59%) | 0.00% | $0 M | Nov 12, 2026 |
| 21 | IFP Advisors, Inc | 1 | New | 0.00% | $0 M | Oct 16, 2026 |
| 22 | Osaic Holdings, Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 23 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Soligenix, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 76,176 | $0 M | 0.33% | <0.01% | +33% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 81,005 | $0 M | 0.35% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 14,459 | $0 M | 0.06% | <0.01% | +43% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 8,054 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Soligenix, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, Director | Buy | +15,132 | $1.320 | $20 K | 15,511 | Form 4 |
| filed | Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, Director | Buy | +20,000 | $0.440 | $9 K | 90,095 | Form 4 |
| filed | Richard StraubeSENIOR VICE PRESIDENT AND CMO | Buy | +8,000 | $0.500 | $4 K | 8,000 | Form 4 |
| filed | Christopher J. SchaberCHAIRMAN, CEO AND PRESIDENT, Director | Buy | +7,000 | $0.740 | $5 K | 70,095 | Form 4 |
| filed | Jonathan L. GuarinoSenior Vice President and CFO | Buy | +1,000 | $0.700 | $700 | 11,000 | Form 4 |
| filed | Jonathan L. GuarinoSenior Vice President and CFO | Buy | +10,000 | $0.710 | $7 K | 10,000 | Form 4 |
| filed | Christopher J. SchaberChairman, CEO and President, Director | Buy | +10,000 | $0.730 | $7 K | 63,095 | Form 4 |
| filed | Jerome B. ZeldisDirector | Buy | +3,000 | $0.890 | $3 K | 25,917 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Soligenix, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-16 reverse split ; 1-for-14.93 reverse split
Trading halts
- 2026-04-28 11:25 UTC, code T3, resumed 12:00 UTC
- 2025-01-14 14:41 UTC, code LUDP, resumed 14:46 UTC
- 2025-01-14 14:34 UTC, code LUDP, resumed 14:39 UTC
Fails to deliver
- : 7,919 shares at $0.37
- : 3,833 shares at $0.35
- : 11,933 shares at $0.37
- : 3,564 shares at $0.36
- : 25,401 shares at $0.35
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Soligenix, Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-118.8%Free cash flow is -118.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.14 vs -4.98Diluted EPS -2.14 in fiscal 2025 against -4.98 the year before (report's currency).
- ✓Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$18 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-235.5%-235.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year212.6%Diluted shares up 212.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Soligenix, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | 0.1−85.8%100% | 0.8−11.5%100% | 0.9+15.1%100% | 0.8−65.1%100% | 2.4−49.0%100% | 4.6−11.7%100% | 5.2−3.5%100% | 5.4−48.0%100% | 10—100% | |
| Cost of revenue | — | 0.1−83.9%100% | 0.7+34.7%88.4% | 0.6−24.4%58.0% | 0.7−60.0%88.4% | 1.8−49.0%77.2% | 3.6−22.4%77.1% | 4.6+6.7%87.7% | 4.3−48.9%79.3% | 8.4—80.7% | |
| Gross profit | — | — | 0.1−75.6%11.6% | 0.4+316%42.0% | 0.1−82.2%11.6% | 0.5−49.3%22.8% | 1.1+65.1%22.9% | 0.6−42.6%12.3% | 1.1−44.3%20.7% | 2.0—19.3% | |
| Research and development | 7.5+43.3%— | 5.2+57.7%4376% | 3.3−58.3%395% | 7.9−3.0%837% | 8.2r8.4−16.4%993% | 9.8r10+20.6%415% | 8.1+20.3%175% | 6.8+22.6%129% | 5.5+28.2%101% | 4.3—41.1% | |
| General and administrative | 4.4+3.4%— | 4.2−5.9%3532% | 4.5−33.0%534% | 6.7+33.6%705% | 5.0r4.8+15.7%608% | 4.3r4.0+24.4%183% | 3.5+17.9%75.2% | 3.0−8.0%56.3% | 3.2−6.4%59.1% | 3.4—32.8% | |
| Operating expenses | 12+25.5%— | 9.4+21.1%7908% | 7.8−46.7%929% | 15+10.9%1543% | 13r13−31.0%1601% | 19+64.8%811% | 12+19.6%251% | 9.7+11.3%185% | 8.7+12.8%160% | 7.7—73.9% | |
| Operating income | −12—— | −9.4—−7908% | −7.7—−917% | −14—−1501% | −13r−13—−1589% | −19—−788% | −11—−228% | −9.1—−173% | −7.6—−140% | −5.7—−54.6% | |
| Interest and finance income | — | — | — | — | — | — | 0.1−6.1%3.2% | 0.2—3.0% | — | — | |
| Interest expense and finance costs | — | — | — | — | — | 0.0—1.5% | — | — | — | — | |
| Net interest income | — | — | — | — | −0.9—−105% | −0.0−107%−0.5% | 0.1—3.2% | — | — | 0.0—0.0% | |
| Other non-operating income (expense) | 0.3−66.2%— | 0.8—640% | −0.2—−25.1% | −0.7—−75.3% | −0.3r−0.3−618%−38.4% | 0.1−89.4%2.6% | 0.6+261%12.4% | 0.2+432%3.0% | 0.0−98.5%0.6% | 1.9—18.5% | |
| Income before tax | −12—— | −8.7—−7268% | −7.9—−942% | −15—−1576% | −13—−1628% | −19—−785% | −10.0—−215% | −8.9—−170% | −7.6—−139% | −3.8—−36.1% | |
| Income tax | −0.5—— | −0.4—−343% | −1.8—−211% | −1.2—−122% | −0.9—−105% | −0.8—−35.5% | −0.6—−13.2% | — | −0.4—−7.7% | −0.5—−5.1% | |
| Net income including minority interests | −11—— | −8.3—−6925% | −6.1—−732% | −14—−1454% | −13—−1523% | — | — | — | — | — | |
| Net income attributable to shareholders | −11—— | −8.3—−6925% | −6.1—−732% | −14—−1454% | −13—−1523% | −18—−750% | −9.4—−202% | −8.9—−170% | −7.1—−132% | −3.2—−31.1% | |
| Earnings per share, basic | -2.14—— | -4.98—— | -12.66r-0.79—— | -4.81—— | -4.69r-0.31—— | -0.64—— | -0.48—— | -0.68—— | -1.16—— | -0.93—— | |
| Earnings per share, diluted | -2.14—— | -4.98—— | -12.66r-0.79—— | -4.81—— | -4.69r-0.31—— | -0.64—— | -0.48—— | -0.68—— | -1.16—— | -1.34—— | |
| Shares, weighted average (basic) | 5.2+213%— | 1.7+242%— | 0.5r7.8−83.1%— | 2.9+7.3%— | 2.7r40−90.3%— | 27—— | — | — | 6.1+76.5%— | 3.5—— | |
| Shares, weighted average (diluted) | 5.2+213%— | 1.7+242%— | 0.5r7.8−83.1%— | 2.9+7.3%— | 2.7r40−90.3%— | 27+41.9%— | 19+47.0%— | 13+114%— | 6.1+71.5%— | 3.6—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.9+1.5%85.9% | 7.8−7.4%87.2% | 8.4−36.8%86.2% | 13−48.7%93.6% | 26+39.4%96.9% | 19+245%93.9% | 5.4−39.7%69.7% | 9.0+15.0%85.6% | 7.8−11.0%81.8% | 8.8—85.4% | |
| Current assets | 8.8+0.2%95.8% | 8.8−7.1%98.5% | 9.5−31.4%97.0% | 14−47.9%97.0% | 27+36.5%98.9% | 19+160%97.9% | 7.5−27.5%96.4% | 10+9.8%98.6% | 9.4−6.9%98.6% | 10—98.5% | |
| Property, plant and equipment | 0.0+43.5%0.1% | 0.0−48.7%0.1% | 0.0−35.5%0.1% | 0.0−16.8%0.1% | 0.0−5.5%0.1% | 0.0−34.9%0.1% | 0.0+83.8%0.5% | 0.0−47.2%0.2% | 0.0+39.2%0.4% | 0.0—0.3% | |
| Right-of-use (leased) assets | 0.4+226%3.8% | 0.1−52.6%1.2% | 0.2−32.6%2.3% | 0.3+221%2.4% | 0.1−52.3%0.4% | 0.2+97.9%1.1% | 0.1r0.1−52.3%1.4% | 0.2r0.2—2.2% | — | — | |
| Other intangible assets | — | — | — | — | — | — | 0.0−58.0%0.3% | 0.0−36.6%0.4% | 0.1−41.6%0.8% | 0.1—1.2% | |
| Total assets | 9.2+3.0%100% | 9.0−8.5%100% | 9.8−31.4%100% | 14−46.9%100% | 27+35.1%100% | 20+156%100% | 7.8−25.9%100% | 10+9.9%100% | 9.5−7.0%100% | 10—100% | |
| Accounts payable | 1.1+67.0%12.1% | 0.7−39.9%7.4% | 1.1−71.3%11.3% | 3.9+32.1%27.1% | 2.9+37.4%10.9% | 2.1−22.1%10.7% | 2.7+28.7%35.2% | 2.1+21.2%20.3% | 1.8+2.7%18.4% | 1.7—16.6% | |
| Customer deposits | — | — | — | — | 0.3−75.0%0.9% | 1.00.0%5.0% | 1.00.0%12.9% | 1.00.0%9.5% | 1.00.0%10.5% | 1.0—9.7% | |
| Current liabilities | 3.7−23.7%40.1% | 4.8−21.2%54.1% | 6.2−62.8%62.8% | 17+163%116% | 6.3+3.5%23.4% | 6.1−3.7%30.6% | 6.3+49.9%81.2% | 4.2+30.4%40.1% | 3.2+12.5%33.8% | 2.9—28.0% | |
| Lease liabilities (non-current) | 0.2—2.6% | — | 0.1−52.1%1.1% | 0.2—1.6% | — | — | — | — | — | — | |
| Total liabilities | 3.9−18.7%42.7% | 4.8−33.4%54.1% | 7.3−56.6%74.3% | 17+3.7%117% | 16−0.0%60.1% | 16+156%81.2% | 6.3+50.0%81.3% | 4.2—40.1% | — | — | |
| Retained earnings | −245—−2653% | −234—−2609% | −226—−2304% | −220—−1538% | −206—−766% | −193—−971% | −176—−2257% | −166—−1584% | −157—−1647% | −150—−1462% | |
| Shareholders' equity | 5.3+28.5%57.3% | 4.1+63.3%45.9% | 2.5—25.7% | −2.5−123%−17.3% | 11+187%39.9% | 3.7+157%18.8% | 1.5−76.8%18.7% | 6.3−0.6%59.9% | 6.3−14.6%66.2% | 7.4—72.0% | |
| Total liabilities and equity | 9.2+3.0%100% | 9.0−8.5%100% | 9.8−31.4%100% | 14−46.9%100% | 27+35.1%100% | 20+156%100% | 7.8−25.9%100% | 10+9.9%100% | 9.5−7.0%100% | 10—100% | |
| Shares outstanding | 10+301%— | 2.5+288%— | 0.6r10−77.7%— | 2.9+1.8%— | 2.9r43−90.7%— | 31+40.9%— | 22r22+23.0%— | 18+103%— | 8.7+59.6%— | 5.5—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | 0.0−45.2%4.1% | 0.1+14.5%2.6% | 0.1+23.6%1.2% | 0.0−35.7%0.8% | 0.1−23.8%1.3% | 0.1—0.9% | |
| Share-based compensation | 0.6+78.2%— | 0.3−10.9%276% | 0.4+11.0%44.1% | 0.3−7.8%35.1% | 0.4−11.8%43.9% | 0.4+8.9%17.4% | 0.4−1.2%8.1% | 0.4−22.2%7.3% | 0.5−14.8%9.0% | 0.6—5.5% | |
| Cash from operating activities | −10—— | −8.4—−7040% | −8.6—−1025% | −13—−1333% | −12—−1424% | −11—−485% | −7.5—−162% | −7.2—−138% | −6.5—−120% | −5.0—−47.7% | |
| Capital expenditure | −0.0—— | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −0.0—— | — | — | −0.0—−1.4% | −0.0—−1.4% | −0.0—−0.3% | −0.0—−0.5% | −0.0—−0.0% | −0.0—−0.5% | −0.0—−0.1% | |
| Shares issued | — | — | — | — | — | — | — | — | — | 3.0—28.7% | |
| Cash from financing activities | 10+33.8%— | 7.8+112%6502% | 3.7+4669%436% | 0.1−99.6%8.1% | 19−22.8%2312% | 25+516%1046% | 4.0−52.4%86.5% | 8.4+51.1%161% | 5.6−37.0%103% | 8.8—84.6% | |
| Exchange-rate effect on cash | — | 0.0−45.2%12.5% | 0.0—3.2% | −0.1−263%−10.4% | 0.1+48.3%7.4% | 0.0—1.7% | −0.0—−0.7% | −0.0—−0.1% | — | — | |
| Change in cash | 0.1—— | −0.6—−525% | −4.9—−585% | −13−272%−1337% | 7.4−44.4%894% | 13—562% | −3.6−403%−77.0% | 1.2—22.4% | −1.0−125%−17.7% | 3.9—36.9% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | 0*−100%— | 0*—— | 0.0—100% | 0.1—100% | 0.2*—100% | |
| Cost of revenue | — | — | — | — | — | — | — | — | 0*−100%— | 0*—— | 0.0—100% | 0.1—100% | 0.2*—90.5% | |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | 0.0*—9.5% | |
| Research and development | 5.4−31.4%— | 0.4−77.5%— | 1.0−41.9%— | 1.8−8.2%— | 2.3*−14.1%— | 1.6+63.5%— | 1.7+235%— | 1.9r2.2+77.3%— | 2.7*+242%— | 1.0—— | 0.5—21399% | 1.1—936% | 0.8*—318% | |
| General and administrative | 4.4+5.1%— | 1.0+2.2%— | 1.1+3.5%— | 1.1+1.6%— | 1.2*+13.1%— | 1.0+11.2%— | 1.1−12.6%— | 1.1+6.1%— | 1.1*−23.8%— | 0.9—— | 1.2—53096% | 1.0—873% | 1.4*—565% | |
| Operating expenses | 9.8−18.6%— | 1.4−46.7%— | 2.1−24.0%— | 2.9−4.7%— | 3.5*−6.4%— | 2.6+38.3%— | 2.8+58.4%— | 3.0r3.3+43.0%— | 3.7*+71.8%— | 1.9—— | 1.7—74495% | 2.1—1809% | 2.2*—883% | |
| Operating income | −9.8—— | −1.4—— | −2.1—— | −2.9—— | −3.5*—— | −2.6—— | −2.8—— | −3.0r−3.3—— | −3.7*—— | −1.9—— | −1.7—−74495% | −2.1—−1809% | −2.1*—−873% | |
| Other non-operating income (expense) | 0.5−0.1%— | 0.3+421%— | 0.1+81.1%— | 0.1−20.4%— | 0.1*−77.3%— | 0.0−66.0%— | 0.1−38.2%— | 0.1−62.7%— | 0.3*—— | 0.1—— | 0.1—4277% | 0.2—172% | −0.3*—−118% | |
| Income before tax | −9.3—— | −1.1—— | −2.0—— | −2.8—— | −3.4*—— | −2.5—— | −2.7—— | −3.0r−3.2—— | −3.4*—— | −1.7—— | −1.6—−70218% | −1.9—−1637% | −2.4*—−991% | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | −0.6*—−248% | |
| Net income including minority interests | −8.8—— | −1.1*—— | −2.0*—— | −2.8—— | −2.9*—— | −2.5*—— | −2.7r−2.4*—— | −3.0r−3.2—— | −3.0*—— | −1.7*—— | −1.6*—−70218% | −1.9—−1637% | −1.8*—−743% | |
| Net income attributable to shareholders | −8.8—— | −1.1—— | −2.0—— | −2.8—— | −2.9*—— | −2.5—— | −2.7—— | −3.0r−3.2—— | −3.0*—— | −1.7—— | −1.6—−70218% | −1.9—−1637% | −1.8*—−743% | |
| Earnings per share, basic | — | -0.05—— | -0.12—— | -0.28—— | — | -0.58—— | -0.82—— | -0.97r-1.06—— | — | -0.78—— | -1.31—— | -2.91r-0.18—— | — | |
| Earnings per share, diluted | — | -0.05—— | -0.12—— | -0.28—— | — | -0.58—— | -0.82—— | -0.97r-1.06—— | — | -0.78—— | -1.31—— | -2.91r-0.18—— | — | |
| Shares, weighted average (basic) | 22+412%— | 22+412%— | 16+387%— | 10+233%— | — | 4.3+96.5%— | 3.3+160%— | 3.0+364%— | — | 2.2—— | 1.3—— | 0.7r11—— | — | |
| Shares, weighted average (diluted) | 22+412%— | 22+412%— | 16+387%— | 10+233%— | — | 4.3+96.5%— | 3.3+160%— | 3.0+364%— | — | 2.2—— | 1.3—— | 0.7r11—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 9.0—95.3% | 9.0−14.3%95.3% | 9.8+92.5%93.4% | 6.0−17.4%87.1% | 7.9+1.5%85.9% | 11+7.0%114% | 5.1−45.8%88.5% | 7.3+2.9%94.2% | 7.8−7.4%87.2% | 9.8—93.9% | 9.4—95.4% | 7.1—88.0% | 8.4—86.2% | |
| Current assets | 9.2—96.9% | 9.2−15.7%96.9% | 10+91.2%96.9% | 6.6−14.1%94.8% | 8.8+0.2%95.8% | 11+5.6%118% | 5.3−44.9%92.4% | 7.6−2.3%98.6% | 8.8−7.1%98.5% | 10—98.4% | 9.7—98.0% | 7.8—97.0% | 9.5—97.0% | |
| Property, plant and equipment | 0.0—0.1% | 0.0−29.9%0.1% | 0.0−18.9%0.1% | 0.0+39.4%0.1% | 0.0+43.5%0.1% | 0.0+9.1%0.1% | 0.0−7.3%0.1% | 0.0−46.8%0.1% | 0.0−48.7%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | 0.3—2.8% | 0.3−29.6%2.8% | 0.3−27.1%2.8% | 0.3+324%4.7% | 0.4+226%3.8% | 0.4+173%4.1% | 0.4+140%7.1% | 0.1−61.6%1.0% | 0.1−52.6%1.2% | 0.1—1.3% | 0.2—1.7% | 0.2—2.5% | 0.2—2.3% | |
| Total assets | 9.5—100% | 9.5+2.5%100% | 10+82.3%100% | 6.9−10.6%100% | 9.2+3.0%100% | 9.2r11−11.8%100% | 5.8−41.6%100% | 7.7−3.9%100% | 9.0−8.5%100% | 10—100% | 9.9—100% | 8.1—100% | 9.8—100% | |
| Accounts payable | 1.7—18.1% | 1.7+42.0%18.1% | 1.4+117%13.4% | 0.8+38.2%12.0% | 1.1+67.0%12.1% | 1.2+35.4%13.1% | 0.6−61.7%11.3% | 0.6−58.3%7.7% | 0.7−39.9%7.4% | 0.9—8.5% | 1.7—17.2% | 1.4—17.8% | 1.1—11.3% | |
| Current liabilities | 3.1—32.3% | 3.1−10.6%32.3% | 3.7+1.2%35.0% | 3.6—52.3% | 3.7−23.7%40.1% | 3.4−24.5%37.1% | 3.6−42.9%63.0% | — | 4.8−21.2%54.1% | 4.5—43.2% | 6.4—64.4% | 7.2—89.5% | 6.2—62.8% | |
| Lease liabilities (non-current) | 0.2—1.6% | 0.2−45.2%1.6% | 0.2−39.8%1.7% | 0.2—3.1% | 0.2—2.6% | 0.3+2273%3.0% | 0.3+562%5.3% | — | — | 0.0—0.1% | 0.0—0.5% | 0.1—1.0% | 0.1—1.1% | |
| Total liabilities | 3.2—33.9% | 3.2−13.2%33.9% | 3.9−2.0%36.7% | 3.8−0.4%55.4% | 3.9−18.7%42.7% | 3.7−18.6%40.0% | 3.9−38.6%68.3% | 3.8r4.1−47.2%49.7% | 4.8−33.4%54.1% | 4.5—43.4% | 6.4—64.9% | 7.3—90.5% | 7.3—74.3% | |
| Retained earnings | −251—−2652% | −251—−2652% | −250—−2380% | −248—−3581% | −245—−2653% | −242—−2622% | −240—−4160% | −237—−3062% | −234—−2609% | −231—−2205% | −229—−2324% | −228—−2825% | −226—−2304% | |
| Shareholders' equity | 6.3—66.1% | 6.3−17.7%66.1% | 6.6+263%63.3% | 3.1−20.7%44.6% | 5.3+28.5%57.3% | 7.6+28.0%82.3% | 1.8−47.2%31.7% | 3.9r3.6+407%50.3% | 4.1+63.3%45.9% | 5.9—56.6% | 3.5—35.1% | 0.8—9.5% | 2.5—25.7% | |
| Total liabilities and equity | 9.5—100% | 9.5−16.2%100% | 10+82.3%100% | 6.9−10.6%100% | 9.2+3.0%100% | 11+7.8%122% | 5.8−41.6%100% | 7.7−3.9%100% | 9.0−8.5%100% | 10—100% | 9.9—100% | 8.1—100% | 9.8—100% | |
| Shares outstanding | 23—— | 23+137%— | 22+517%— | 11+230%— | 10+301%— | 9.9+330%— | 3.5+127%— | 3.2−69.7%— | 2.5+288%— | 2.3—— | 1.5—— | 11—— | 0.6r10—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.6+52.2%— | 0.1*−17.0%— | 0.1*+16.5%— | 0.1+90.6%— | 0.3*+106%— | 0.1*+84.3%— | 0.1*+72.5%— | 0.1+6.1%— | 0.2*+10.2%— | 0.1—— | 0.1—2463% | 0.1—51.2% | 0.1*—57.6% | |
| Cash from operating activities | −8.2—— | −1.4*—— | −1.7*—— | −2.4—— | −2.7*—— | −2.9*—— | −2.7*—— | −1.8—— | −2.2*—— | −2.9*—— | −1.9*—−81888% | −1.3—−1147% | −1.8*—−747% | |
| Capital expenditure | — | — | — | — | −0.0*—— | −0.0*—— | — | — | — | — | — | — | — | |
| Cash from investing activities | — | — | — | — | −0.0*—— | −0.0*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 6.7−35.7%— | 0.6*−92.4%— | 5.5*+906%— | 0.5−66.0%— | 0.2*−35.0%— | 8.4*+154%— | 0.5*−87.1%— | 1.3—— | 0.2*—— | 3.3*—— | 4.2*—180818% | −0.0—−7.7% | −0.0*—−18.9% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | −0.0*−239%— | 0.0*—— | 0.0*—173% | −0.0—−2.7% | 0.0*—9.0% | |
| Change in cash | −1.5−319%— | −0.8*−115%— | 3.8*—— | −1.9—— | −2.6*—— | 5.4*+1169%— | −2.2*−195%— | −0.5—— | −2.0*—— | 0.4*—— | 2.3*—99103% | −1.4—−1157% | −1.9*—−757% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Soligenix, Inc. sells: revenue by product line, fiscal 2024#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Grant revenue$0 M100%—
Business segments
- Specialized BioTherapeutics$0 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2024
Where Soligenix, Inc. operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office3 subsidiaries | — |
| 🇨🇦 Canada | 1 subsidiary | — |
| 🇳🇱 Netherlands | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Soligenix, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Christopher J. Schaber | $1.1 M | $1.2 M | $421 K | $1 |
| 2024Christopher J. Schaber | $833 K | $697 K | $367 K | $2 |
| 2023Christopher J. Schaber | $700 K | $531 K | $331 K | $4 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Soligenix, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Directors and officers 3 · Material agreement 5 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 4
| Filed | What happened | Filing |
|---|---|---|
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Agreement ended | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 21, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2017 | $2 M | Private placement after listing | Under $2 million | 6 | equity | SEC |
| Apr 2013 | $2 M | Private placement after listing | Under $2 million | 1 | equity | SEC |
| Jun 2010 | $6 M | No. 4 | $2 to $10 million | 46 | equity, options | SEC |
| Feb 2009 | $5 M | No. 3 | $2 to $10 million | 1 | equity | SEC |
| Jan 2009 | $2 M | No. 2 | $2 to $10 million | 6 | equity, options | SEC |
| Dec 2008 | $2 M | No. 1 | Under $2 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Soligenix, Inc. compares in Biotechnology
- Market cap$9 M · higher than 9% of 726
- Revenue growth-11.6% · higher than 33% of 438
- Price / book1.6× · lower than 64% of 534
- FCF yield-118.8% · higher than 8% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Soligenix, Inc.🇺🇸 | $9 M | — | — | -11.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Soligenix, Inc.? Verify and update this profile — free
Show Soligenix, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.